The 10 that are cited most themselves, of 23.
Directive (EU) 2004/27Lawamends
Judgment of the Court (First Chamber) of 9 June 2005. HLH Warenvertriebs GmbH (C-211/03) and Orthica BV (C-299/03 and C-316/03 to C-318/03) Decision
Article 26 of that directive provides: ‘The marketing authorisation shall be refused if, after verification of the particulars and documents listed in Articles 8 and 10(1), it provides that: the medicinal product is harmful in the normal …
9 Jun 2005 · 62003CJ0211
Judgment of the General Court (Third Chamber) of 14 December 2011. Nycomed Danmark ApS v European Medicines Agency (EMA).Decision
It should be noted in that regard that, according to Article 8(3)(e) and Article 11 of Directive 2001/83, which are also applicable to applications for marketing authorisation provided for in Article 6 of Regulation No 726/2004, such …
14 Dec 2011 · 62009TJ0052
Judgment of the Court (Second Chamber) of 14 March 2018. Proceedings brought by Astellas Pharma GmbH.Decision
Secondly, it is clear from Article 19(1) of Directive 2001/83 that, in order to examine an application under Article 10 of that directive, the competent authority of a Member State must verify whether the file submitted complies with that …
14 Mar 2018 · 62016CJ0557
BVerwG, Urteil vom 1. Dezember 2016 - 3 C 14/15Decision
… 2 AMG. Die Neufassung des § 25 Abs. 2 Satz 1 Nr. 5 AMG durch das 14. Arzneimitteländerungsgesetz setzte Art. 26 Abs. 1 Buchst. a der Richtlinie 2001/83/EG um. Eine inhaltliche Abweichung gegenüber der bislang geltenden Bestimmung war …
1 Dec 2016 · WBRE201700245
Order of the President of the Court of First Instance of 24 April 2009. Nycomed Danmark ApS v Agence européenne des médicaments (EMEA).Decision
24 Apr 2009 · 62009TO0052
Judgment of the General Court (Tenth Chamber) of 23 September 2020 (Extracts). Medac Gesellschaft für klinische Spezialpräparate mbH v EuropDecision
In that regard, it must be stated that a medicinal product’s SmPC cannot but be interpreted strictly. Before granting an MA, including in the context of the variation or extension of an existing MA, the competent authority must ensure, …
23 Sep 2020 · 62019TJ0549
Judgment of the General Court (Sixth Chamber) of 19 December 2019. Vanda Pharmaceuticals Ltd v European Commission.Decision
It is apparent from a combined reading of Article 1(28a) and Article 26 of Directive 2001/83, as well as Article 12 of Regulation No 726/2004, read in the light of recital 14 of that regulation, that an MA is to be refused where, after …
19 Dec 2019 · 62018TJ0211
BVerwG, Urteil vom 7. November 2019 - 3 C 19/18Decision
… § 25 Abs. 2 Satz 1 Nr. 4 und Satz 3 AMG und Erwägungsgrund 7, Art. 26 Abs. 1 Buchst. b der Richtlinie 2001/83/EG). Er ist auf die klinische Prüfung der vom Arzneimittelhersteller beanspruchten Indikation bezogen (vgl. BVerwG, Urteil vom …
7 Nov 2019 · WBRE202000139
Opinion of Mr Advocate General Geelhoed delivered on 3 February 2005. HLH Warenvertriebs GmbH (C-211/03) and Orthica BV (C-299/03 and C-316/Decision
If a product falls within the Community definition of a medicinal product, then for market access purposes the provisions of Directive 2001/83 apply. According to the directive, a medicinal product may be placed on the market only if an …
3 Feb 2005 · 62003CC0211